337 related articles for article (PubMed ID: 36576563)
1. SGLT-2 inhibitors and euglycemic diabetic ketoacidosis/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment.
He Z; Lam K; Zhao W; Yang S; Li Y; Mo J; Gao S; Liang D; Qiu K; Huang M; Wu J
Acta Diabetol; 2023 Mar; 60(3):401-411. PubMed ID: 36576563
[TBL] [Abstract][Full Text] [Related]
2. Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes Mellitus Receiving Oral Therapy.
Dull RB; Spangler ML; Knezevich EL; Lau BM
J Pharm Pract; 2019 Apr; 32(2):240-243. PubMed ID: 29241389
[TBL] [Abstract][Full Text] [Related]
3. Sodium glucose co-transporter-2 inhibitor-induced diabetic ketoacidosis following tooth extraction: improving awareness among dental practitioners.
Yap SD; Hamblin PS; Bach L; Ekinci E; Wong R
Aust Dent J; 2021 Dec; 66(4):444-447. PubMed ID: 34432892
[TBL] [Abstract][Full Text] [Related]
4. SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort.
Ata F; Yousaf Z; Khan AA; Razok A; Akram J; Ali EAH; Abdalhadi A; Ibrahim DA; Al Mohanadi DHSH; Danjuma MI
Sci Rep; 2021 May; 11(1):10293. PubMed ID: 33986421
[TBL] [Abstract][Full Text] [Related]
5. Sodium-glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis; from Pathophysiology to Clinical Practice.
Patoulias D; Manafis A; Mitas C; Avranas K; Lales G; Zografou I; Sambanis C; Karagiannis A
Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):139-146. PubMed ID: 29412120
[TBL] [Abstract][Full Text] [Related]
6. A series of diabetic ketoacidosis associated with the use of sodium-glucose co-transporter-2 inhibitors in secondary care.
Taverner S; Eng C; Watson R; George S; Edwards A; Williams DM; Stephens JW
Diabetes Metab Syndr; 2022 Dec; 16(12):102658. PubMed ID: 36371968
[TBL] [Abstract][Full Text] [Related]
7. Euglycaemic diabetic ketoacidosis as a complication of SGLT-2 inhibitors: epidemiology, pathophysiology, and treatment.
Sampani E; Sarafidis P; Papagianni A
Expert Opin Drug Saf; 2020 Jun; 19(6):673-682. PubMed ID: 32521174
[TBL] [Abstract][Full Text] [Related]
8. Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review.
Bamgboye AO; Oni IO; Collier A
Eur J Clin Pharmacol; 2021 May; 77(5):651-657. PubMed ID: 33244632
[TBL] [Abstract][Full Text] [Related]
9. Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus: A case report.
Lee IH; Ahn DJ
Medicine (Baltimore); 2020 May; 99(21):e20228. PubMed ID: 32481295
[TBL] [Abstract][Full Text] [Related]
10. Hyperglycemic, high anion-gap metabolic acidosis in patients receiving SGLT-2 inhibitors for diabetes management.
Kum-Nji JS; Gosmanov AR; Steinberg H; Dagogo-Jack S
J Diabetes Complications; 2017 Mar; 31(3):611-614. PubMed ID: 27913012
[TBL] [Abstract][Full Text] [Related]
11. Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review.
Sampani E; Sarafidis P; Dimitriadis C; Kasimatis E; Daikidou D; Bantis K; Papanikolaou A; Papagianni A
BMC Nephrol; 2020 Jul; 21(1):276. PubMed ID: 32669085
[TBL] [Abstract][Full Text] [Related]
12. Empagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes Mellitus.
Chauhan S; Manov A; Dhillon GS; Shah P
Cureus; 2023 Jan; 15(1):e33892. PubMed ID: 36819400
[TBL] [Abstract][Full Text] [Related]
13. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis : A Multicenter Cohort Study.
Douros A; Lix LM; Fralick M; Dell'Aniello S; Shah BR; Ronksley PE; Tremblay É; Hu N; Alessi-Severini S; Fisher A; Bugden SC; Ernst P; Filion KB;
Ann Intern Med; 2020 Sep; 173(6):417-425. PubMed ID: 32716707
[TBL] [Abstract][Full Text] [Related]
14. "The Bitter Truth of Sugar"-Euglycemic Diabetic Ketoacidosis due to Sodium-glucose Cotransporter-2 Inhibitors: A Case Series.
Shah M; Pathrose E; Bhagwat NM; Chandy D
Indian J Crit Care Med; 2022 Jan; 26(1):123-126. PubMed ID: 35110855
[TBL] [Abstract][Full Text] [Related]
15. Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials.
Monami M; Nreu B; Zannoni S; Lualdi C; Mannucci E
Diabetes Res Clin Pract; 2017 Aug; 130():53-60. PubMed ID: 28570924
[TBL] [Abstract][Full Text] [Related]
16. "Normal but Catastrophic" Euglycemic Diabetic Ketoacidosis Precipitated by Sodium-Glucose Cotransporter-2 Inhibitor Use: A Case Report.
Sarno MJF; Hernandez DPF; Matulac MO
Cureus; 2023 Nov; 15(11):e49236. PubMed ID: 38143642
[TBL] [Abstract][Full Text] [Related]
17. [Severe SGLT-2 inhibitor-induced euglycemic ketoacidosis-a rare but serious complication].
Rotsel E; Pietsch U
Anaesthesist; 2020 Jan; 69(1):49-51. PubMed ID: 31807797
[TBL] [Abstract][Full Text] [Related]
18. Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies.
Li CX; Liu TT; Zhang Q; Xie Q; Geng XH; Man CX; Li JY; Mao XY; Qiao Y; Liu H
Front Pharmacol; 2023; 14():1275060. PubMed ID: 37905204
[No Abstract] [Full Text] [Related]
19. Clinical and biochemical characteristics and analysis of risk factors for euglycaemic diabetic ketoacidosis in type 2 diabetic individuals treated with SGLT2 inhibitors: A review of 72 cases over a 4.5-year period.
Menghoum N; Oriot P; Hermans MP
Diabetes Metab Syndr; 2021; 15(6):102275. PubMed ID: 34562870
[TBL] [Abstract][Full Text] [Related]
20. Drug-Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data.
Alkabbani W; Pelletier R; Beazely MA; Labib Y; Quan B; Gamble JM
Drug Saf; 2022 Mar; 45(3):287-295. PubMed ID: 35247195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
